Less myopia seen after anti-VEGF treatment for ROP

July 2013
Ocular Surgery News;7/10/2013, Vol. 31 Issue 13, p14
Academic Journal
The article reports on a study in 2013 indicating that less myopia was seen with intravitreal bevacizumab injections than with laser or cryotherapy in infants with retinopathy of prematurity.


Related Articles

  • Anti-VEGF therapy superior to laser for preventing recurrences of retinopathy of prematurity. KUZNAR, WAYNE // Contemporary Pediatrics;Mar2011, Vol. 28 Issue 3, p14 

    No abstract available.

  • Structural sequelae and refractive outcome 1 year aft er laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes. Katoch, Deeksha; Sanghi, Gaurav; Dogra, Mangat R.; Beke, Nikhil; Gupta, Amod // Indian Journal of Ophthalmology;Nov2011, Vol. 59 Issue 6, p423 

    The aim was to study the structural sequelae and refractive outcome aft er laser treatment for Type 1 prethreshold retinopathy of prematurity (ROP) in Asian Indian eyes. Materials and Methods: A retrospective chart review of infants with Type 1 prethreshold ROP (defi ned according to the Early...

  • Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity. Kim, Rebecca; Yu Cheol Kim // Journal of Ophthalmology;2014, p1 

    Purpose. To report the results of the posterior pole sparinglaser photocoagulation combined with intravitreal bevacizumab injection (IVB) in retinopathy of prematurity (ROP). Methods. A retrospective chart review of premature babies with ROP, all of whom received laser photocoagulation with IVB....

  • An interventional comparative.  // Review of Ophthalmology;Aug2013, Vol. 20 Issue 8, p74 

    The article focuses on a comparative study of refractive error in infants who underwent a single intravitreal bevacizumab injection for treatment of threshold retinopathy of prematurity, which reveals that bevacizumab is more useful than retinal laser coagulation as it causes less astigmatism.

  • ROP can have lifetime ophthalmic implications. Bechtel, Bryan; Boyle, Erin L.; Hasson, Matt // Ocular Surgery News Europe;Jan2011, Vol. 22 Issue 1, p18 

    The article discloses the impact of retinopathy of prematurity (ROP) in people since infancy to eye conditions myopia and cataracts, which was addressed by William S. Tasman at the 2010 Schepens Lecture during the Retina Subspecialty Day.

  • Severe ROP can lead to high myopia, despite early treatment. Loughery, Jessica // Ocular Surgery News;10/25/2008, Vol. 26 Issue 20, p89 

    The article discusses research being done on the progression of myopia and high myopia in the early treatment for retinopathy of prematurity (ROP). It references a study by Graham E. Quinn and colleagues published in a 2008 issue of the journal "Ophthalmology." Researchers found that infants...

  • Lens development studied in ROP myopia. Sabbagh, Leslie // Ophthalmology Times;1/23/95, Vol. 20 Issue 4, p11 

    Highlights the results of the study conducted by Jeff Hansen, regarding the anterior segment structures of myopia associated with retinopathy of prematurity (ROP). Use of age-matched controls; Measurement of corneal refractive power, anterior chamber depth, lens thickness and axial length; Use...

  • FOCUS ON RETINOPATHY OF PREMATURITY IN NORTHERN IRELAND.  // Journal of Visual Impairment & Blindness;Oct2010, Vol. 104 Issue 10, p666 

    The article reports on the study on vision loss prevention in premature babies being conducted by researchers at Queen's University Belfast in Northern Ireland. The said study, which received financial assistance from Fight for Sight organization, aims to discover a therapeutic option that can...

  • Intravitreal injection of bevacizumab for retinopathy of prematurity. Kuniyoshi, Kazuki; Sugioka, Koji; Sakuramoto, Hiroyuki; Kusaka, Shunji; Wada, Norihisa; Shimomura, Yoshikazu // Japanese Journal of Ophthalmology;May2014, Vol. 58 Issue 3, p237 

    Purpose: To evaluate the outcomes of intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP). Methods: IVB was selected to be the first treatment for type 1 ROP in 8 eyes (4 patients). Bevacizumab (0.25 mg/eye) was injected into the vitreous cavity under either general...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics